Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources by Heller, S.R. et al.
Research: Complications
Severe hypoglycaemia in adults with insulin-treated
diabetes: impact on healthcare resources
S. R. Heller1, B. M. Frier2, M. L. Hersløv3, J. Gundgaard4 and S. C. L. Gough5
1Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, 2The Queen’s Medical Research Institute, University of Edinburgh,
Edinburgh, UK, 3Medical & Science, Novo Nordisk A/S, Søborg, 4Health Economics & HTA, Novo Nordisk A/S, Søborg, Denmark and 5Oxford Centre for Diabetes
Endocrinology and Metabolism, Academic Health Science Network, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
Accepted 23 June 2015
Abstract
Aims To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large
phase 3a clinical programme involving people with Type 1 diabetes treated with basal–bolus insulin, people with
Type 2 diabetes treated with multiple daily injections and people with Type 2 diabetes treated with basal–oral therapy.
Methods Data relating to severe hypoglycaemia events (defined as episodes requiring external assistance) from the
insulin degludec and insulin degludec/insulin aspart programme (15 trials) were analysed using descriptive statistics.
Comparators included insulin glargine, biphasic insulin aspart, insulin detemir and sitagliptin. Mealtime insulin aspart
was used in some regimens. This analysis used the serious adverse events records, which documented the use of
ambulance/emergency teams, a hospital/emergency room visit ≤ 24 h, or a hospital visit > 24 h.
Results In total, 536 severe hypoglycaemia events were analysed, of which 157 (29.3%) involved an ambulance/
emergency team, 64 (11.9%) led to hospital/emergency room attendance of ≤ 24 h and 36 (6.7%) required hospital
admission (> 24 h). Although there were fewer events in people with Type 2 diabetes compared with Type 1 diabetes,
once a severe episode occurred, the tendency to utilize healthcare resources was higher in Type 2 diabetes vs. Type 1
diabetes. A higher proportion (47.6%) in the basal–oral therapy group required hospital treatment for > 24 h versus the
Type 1 diabetes (5.0%) and Type 2 diabetes multiple daily injections (5.3%) groups.
Conclusion This analysis suggests that severe hypoglycaemia events often result in emergency/ambulance calls and
hospital treatment, incurring a substantial health economic burden, and were associated with all insulin regimens.
Diabet. Med. 33, 471–477 (2016)
Introduction
Hypoglycaemia is a major side effect of some glucose-
lowering therapies, in particular, insulin and the insulin
secretagogues (sulphonylureas and glinides). It is a frequent
occurrence in people treated with insulin and is more
common in Type 1 than in Type 2 diabetes [1–3]. Hypo-
glycaemia increases in frequency and severity with the
duration of insulin treatment [3]. Impaired awareness of
hypoglycaemia is common in people treated with insulin,
particularly those with Type 1 diabetes [4].
Hypoglycaemia has a significant burden as it can engender
fear and anxiety, disrupt sleep and adversely affect domestic
and social life [5,6]. Interestingly, rates of severe hypoglyca-
emia have not generally diminished over the years, despite
the introduction of insulin analogues and advances in glucose
monitoring [7,8]. This may be a consequence of the drive to
tighter glucose targets, which have diminished the benefits of
technological advances. Attempting to reduce this burden
can encourage the maintenance of a suboptimal glycaemic
control [5,9,10], and both the severity and frequency of
hypoglycaemia unequivocally reduce health-related quality
of life [11–14]. Hypoglycaemia is also a burden on health-
care resources and on society as a consequence of the direct
costs of its treatment and the indirect costs associated with
lost productivity [9,15,16]. These and other factors can
negatively influence physicians and people with diabetes,
promoting reluctance to initiate or intensify therapy —
insulin in particular — because of the perceived burden of
hypoglycaemia [10,17].
The benefits of stricter glycaemic control are counterbal-
anced by the enhanced risk of concomitant hypoglycaemia.
The most expensive aspect of treating severe hypoglycaemia
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is hospital admission and inpatient care [15,16]. Severe
hypoglycaemia is a common cause of hospitalization in
elderly people with diabetes [18–21]. To our knowledge, no
large-scale studies of the resource use associated with severe
hypoglycaemia have been performed that have examined this
resource use according to type of diabetes and insulin
regimen. The aim of this analysis was to estimate the
resource use attributable to severe hypoglycaemia events in a
large cohort of people with insulin-treated diabetes, using
data from a large-scale clinical trial programme.
Materials and methods
This analysis used data from the insulin degludec (IDeg) and
insulin degludec/insulin aspart (IDegAsp) phase 3a clinical
trial programme, including 15 phase 3a therapeutic confir-
matory trials, which involved more than 8000 participants.
All trials were registered on ClinicalTrials.gov, the trial
protocols were approved by independent ethics committees
or institutional review boards, and written informed consent
was obtained from participants before enrolment. Trials
were undertaken in accordance with the Declaration of
Helsinki and good clinical practice guidelines [22,23]. The
trials were categorized into three groups, depending on the
patient population and the type of insulin regimen: Type 1
diabetes receiving basal–bolus therapy, Type 2 diabetes
receiving multiple daily injections and Type 2 diabetes
receiving basal–oral therapy.
Severe hypoglycaemia events were identified using infor-
mation relating to adverse-event case reports in the clinical
trial safety database. Only clearly stated resource use was
included in the analysis, and all events were analysed
independently. The data were analysed descriptively, taking
into consideration three variables (that are not necessarily
mutually exclusive):
1. Non-medical assistance only, with the response categories:
Yes, No.
2. Ambulance or (onsite) emergency team, with the response
categories: Yes, No.
3. Hospital or emergency room visit, with the response
categories: No, Yes ≤ 24 h, Yes > 24 h.
Given the multiplicity of countries in the trial programme,
it was decided not to attempt to distinguish between hospital
inpatient treatment and emergency room treatment (with
subsequent discharge), because the local procedures varied.
Hospital visits were therefore distinguished solely on dura-
tion (≤ 24 h or > 24 h).
Results
Details of the trials and characteristics of the patient
populations are summarized in Table 1 [24–36]. In general,
people with Type 1 diabetes had a lower mean age, longer
disease duration and lower BMI compared with those with
Type 2 diabetes. Across the 15 open-label, randomized,
treat-to-target clinical trials, severe hypoglycaemia was an
infrequent occurrence: 536 severe hypoglycaemia events
were recorded and analysed from a total of 8364 patient
records. Most occurred in people with Type 1 diabetes
receiving basal–bolus therapy, fewer occurred in those with
Type 2 diabetes on multiple daily injections, and a small
number occurred in people with Type 2 diabetes on basal–
oral therapy (Table 1). One reported event of severe hypo-
glycaemia had a fatal outcome.
Overall, 157/536 (29.3%) of severe hypoglycaemia events
required an ambulance/emergency team (mainly involving
paramedics, but also including physicians, although the
analysis did not distinguish between them) (Table 2). Addi-
tionally, following 100/536 (18.7%) of the severe hypo-
glycaemia events, hospital or emergency room treatment was
required, with 36/536 (6.7% points) of these requiring a
hospital stay of > 24 h (Table 2).
Although fewer events were recorded in people with
Type 2 compared with Type 1 diabetes, once an event
occurred, the proportion resulting in hospital or emergency
room treatment was greatest in the basal–oral therapy
treatment group. Resources were used in relation to
57.1%, 45.3% and 37.9% of severe hypoglycaemia events
in the Type 2 diabetes basal–oral therapy, Type 2 diabetes
multiple daily injections and Type 1 diabetes basal–bolus
groups, respectively (Fig. 1). The greatest difference was in
the proportion of events requiring a hospital stay of > 24 h:
47.6% in the Type 2 diabetes basal–oral therapy, 5.3% for
Type 2 diabetes multiple daily injections, and 5.0% for the
Type 1 diabetes basal–bolus group (Table 2).
Discussion
Poor glycaemic control in diabetes is associated with serious
complications such as sight-threatening retinopathy and
renal failure, and optimizing glycaemic control is fundamen-
What’s new?
 The study is unique in reporting resource use associated
with severe hypoglycaemia from a randomized con-
trolled trial setting, because resource use has previously
been analysed by using registers in which only the
events with resource use have been registered, or by
patient questionnaires.
 Severe hypoglycaemia events with and without
resource use have been collected from a large-scale
clinical trial programme.
 The findings suggest that severe hypoglycaemia often
necessitates the use of emergency/ambulance teams and
hospital treatment, incurring a substantial healthcare
burden, regardless of the type of insulin regimen used.
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tal to minimize this morbidity [37–39]. However, severe
hypoglycaemia, a serious adverse effect of some glucose-
lowering therapies — particularly insulin — can also cause
significant morbidity and have quality of life and economic
consequences.
This analysis utilized data from a large-scale clinical trial
programme and subdivided records by type of diabetes and
also by insulin regimen. This has shown that in the controlled
clinical trial setting, severe hypoglycaemia seldom occurs,
but when it does, it leads to direct healthcare resource use in
~ 40% of cases.
A large difference was observed between the different
regimens in the proportion of people experiencing severe
hypoglycaemia who required hospitalization for > 24 h. The
proportion of participants using resources following a severe
hypoglycaemia event was highest in the people with Type 2
diabetes on basal–oral therapy, despite the overall lower
number of events compared with the patients on multiple
daily injections. This may be because many of the partici-
pants receiving basal–oral therapy (and their family/carers)
were much less experienced in treating severe hypoglyca-
emia. They may be more inclined to seek medical assistance,
in contrast to people with Type 1 diabetes and those with
insulin-treated Type 2 diabetes taking multiple daily injec-
tions who probably have greater experience of exposure to
severe hypoglycaemia. People with diabetes and their family
Table 2 Proportion of severe hypoglycaemia events leading to ambulance, emergency room or hospital visits
Group Total number of events Resource use Number of events (%)
Type 1 diabetes basal–bolus 420 Non-medical assistance only 261 (62.1)
Ambulance/emergency team 130 (31.0)
Hospital or emergency room ≤ 24 h 40 (9.5)
Hospital > 24 h 21 (5.0)
Type 2 diabetes multiple daily injections 95 Non-medical assistance only 52 (54.7)
Ambulance/emergency team 24 (25.3)
Hospital or emergency room ≤ 24 h 22 (23.2)
Hospital > 24 h 5 (5.3)
Type 2 diabetes basal–oral therapy 21 Non-medical assistance only 9 (42.9)
Ambulance/emergency team 3 (14.3)
Hospital or emergency room ≤ 24 h 2 (9.5)
Hospital > 24 h 10 (47.6)
All 536 Non-medical assistance only 322 (60.1)
Ambulance/emergency team 157 (29.3)
Hospital or emergency room ≤ 24 h 64 (11.9)
Hospital > 24 h 36 (6.7)
FIGURE 1 The proportion of severe hypoglycaemia events utilizing medical resources. Medical resource use includes use of ambulance/emergency
team, hospital visit < 24 h and > 24 h. The variables measured were not necessarily mutually exclusive. T1D, Type 1 diabetes; T2D, Type 2
diabetes.
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members in these groups are less likely to seek assistance
because they have learned to cope effectively with this
emergency and the immediate requirements of treating an
episode of severe hypoglycaemia. Furthermore, the people
with Type 2 diabetes included in the trials had a higher mean
age than those with Type 1 diabetes, and this may mean that
more of them had more comorbidities, were frailer and were
more vulnerable to morbidity associated with severe hypo-
glycaemia, so contributing to the longer duration of hospital
admissions. Several studies have shown that hypoglycaemia
requiring hospital treatment is more frequent in the elderly
compared with younger people with diabetes [19–21].
It should also be noted that, in some trials, people with
Type 2 diabetes were taking concomitant oral anti-diabetes
agents, including sulphonylureas, and it is not clear whether
these contributed to any of the severe hypoglycaemia events.
Some specialists believe that hospital admission is necessary
for people who experience severe hypoglycaemia as a
consequence of sulphonylurea therapy, which might account
for some of the hospital attendances by the participants
receiving basal–oral therapy [40,41]. A previous study
observed that the proportion of people for whom emergency
medical assistance was sought was higher in those with
Type 2 diabetes than with Type 1 diabetes (33% vs. 10%)
[2]. A population-based study analysing resource use asso-
ciated with severe hypoglycaemia treated by emergency
medical services in Tayside, Scotland, recorded 260 episodes
over a 12-month period. Of these, 34% involved the
ambulance service alone, 7% were treated by emergency/
primary care services alone and 52% used both. Some 28%
of cases required hospital admission, resulting in hospital
occupancy of 230 bed days [16]. Although this is higher than
the 18.6% who visited hospital in our study, it should be
noted that this Scottish study analysed only those events that
had required emergency medical treatment, thus representing
a more severe end of the spectrum.
The use of medical resources following severe hypoglyca-
emia is costly, considering the large number of people with
insulin-treated diabetes and the extensive use of sulphonyl-
ureas. For example, an estimate of this resource utilization
and associated financial burden based on the 2013–2014 UK
National Health Service tariffs for ‘Admitted Patient Care &
Outpatient Procedures — Diabetes with Hypoglycaemic
Disorders’ equates to £1269 for people aged ≤ 69 years
and £2187 for people aged ≥ 70 years, in addition to £235
for an ambulance transfer. This yields an average cost per
event across treatment regimens of £305 [(11.9% +
6.7%) * £1269 + 29.3% * £235] for people aged ≤ 69 years
and £476 [(11.9% + 6.7%) * £2187 + 29.3% * £235] for
people aged ≥ 70 years [42]. Hypoglycaemia is more costly
in elderly populations with diabetes, who may be much more
susceptible to severe hypoglycaemia, perhaps in relation to
co-existing comorbidities [18–21].
Several other studies using different methodologies have
provided results that are in broad agreement with our study.
Hospitalization is the major cost associated with treating
hypoglycaemia, but costs vary depending on the countries
involved and local practices and procedures. For example,
the costs associated with treating hypoglycaemia in Germany
are higher than elsewhere because people with diabetes are
often admitted to hospital for several days to receive additional
education [43]. The study based in Tayside estimated the
direct costs of treating severe hypoglycaemia— based on £127
for an ambulance, £89 for emergency room treatment and
£218 for each patient admitted to a ward — to be over £13
million per year for the UK in 2003 (equivalent to £17 million
in 2014 prices) [16]. Based on these values, the cost of a single
severe hypoglycaemia event, which required some medical
assistance, has been estimated at £335 [44]. Data obtained
using a questionnaire regarding a participant’s most recent
severe hypoglycaemia event performed in Germany, Spain
and the UK revealed that the cost of treating a person with
Type 2 diabetes (Germany, €533; Spain, €691; UK, €537)
was higher than for a person with Type 1 diabetes (€441,
€577 and €236, respectively) [15]. A US-based study inves-
tigating the cost of hypoglycaemia in people with insulin-
treated Type 2 diabetes estimated the direct costs of severe
events requiring assistance from a healthcare professional as
$1729, whereas those events requiring non-medical assistance
were $242 per event [45].
Most previous studies have been retrospective assessments
of all people with severe hypoglycaemia, and often exclu-
sively those who had utilized additional healthcare resources.
Therefore, they have not consistently stratified people
according to their treatment regimen. Although some of
these studies included cost analyses, they did not include all
severe hypoglycaemia events, so it is difficult to determine
what proportion of events required ambulance and hospital
treatment. This study benefits from its size and the more
accurate and reliable recording associated with controlled
clinical trials, by contrast with data that have been collected
in real-world observational or retrospective studies.
This study has the limitation that the rates of hypoglyca-
emia may be lower than in a real-world setting, because
people at high risk of severe hypoglycaemia or who were
judged by the investigator to have impaired hypoglycaemia
awareness were excluded from the clinical trials. However,
because the examination was not primarily aimed at assess-
ing the risk of events, but rather exploring the consequences
of such an event, it is unclear to what extent such a limitation
would influence the results. Additionally, because of the
global nature of the clinical trials, a huge variation in
healthcare utilization and local procedures are to be
expected, making estimates of resource use difficult to
determine with accuracy. Healthcare utilization in trials is
often protocol driven, but this has not been assumed in this
analysis because of the acute nature of severe hypoglycaemia.
Potential exists for the under-reporting of ambulance use, or
inconsistent reporting of resource use. Although it is known
when people had attended hospital, information about how
ª 2015 The Authors.
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they arrived there was not consistently recorded, so only
clearly stated resource use was included in the analysis. This
study did not attempt to capture length of stay or what
medication was received because this would be healthcare-
sector specific and could be confounded by other comorbid-
ities. The study has reported only the direct resource use
relating to the involvement of emergency services and
hospital treatment and does not include additional blood
glucose measurements, costs of glucagon or intravenous
dextrose, or any subsequent medical consultations that were
necessary following a severe hypoglycaemia episode. These
costs were estimated in a Canadian study [46]. Productivity
loss or the costs of informal caregivers were not measured.
Conclusion
This analysis suggests that severe hypoglycaemia events often
result in emergency/ambulance calls and treatment in hospi-
tal, thereby incurring a substantial economic burden. A high
rate of resource utilization was observed with all insulin
regimens, and although the incidence of severe hypoglyca-
emia events was low, the greatest level of resource use
following an event occurred in people with Type 2 diabetes
on a regimen of basal insulin combined with oral anti-
diabetes drugs.
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